Nirmatrelvir and ritonavir combo cuts COVID-19 risks for high-vulnerability groups
Nirmatrelvir and ritonavir treatment significantly reduces the risk of hospitalization and death from COVID-19 in high-risk individuals, according to a recent JAMA Network Open study.